An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback